<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Youn HY</submitter><funding>National Research Foundation of Korea</funding><pagination>589-598</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9992467</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>32(4)</volume><pubmed_abstract>Kefir yeast, &lt;i>Kluyveromyces marxianus&lt;/i>, has been evaluated for its potential probiotic properties-survivability, non-pathogenicity, and antioxidant and anti-microbial activities. However, host gut microbiota modulation of kefir yeasts remains unclear. Here, we compared kefir yeast strains &lt;i>K&lt;/i>. &lt;i>marxianus&lt;/i> A4 (Km A4) and &lt;i>K. marxianus&lt;/i> A5 (Km A5) with &lt;i>Saccharomyces boulardii&lt;/i> ATCC MYA-796 (Sb MYA-796) by investigating their adherence to colorectal adenocarcinoma (Caco-2) cells and gut microbiota modulation in BALB/c mice. The kefir yeast strains exhibited higher intestinal cell adhesion than Sb MYA-796 (&lt;i>p&lt;/i> &lt; 0.05). Bacteroidetes, Bacteroidales, and &lt;i>Bacteroides&lt;/i> were more abundant in the 1 × 10&lt;sup>8&lt;/sup> CFU/mL of Km A4 treatment group than in the control group (&lt;i>p&lt;/i> &lt; 0.05). Moreover, 1 × 10&lt;sup>8&lt;/sup> CFU/mL of Km A5 increased Corynebacteriales and &lt;i>Corynebacterium&lt;/i> compared to the 1 × 10&lt;sup>8&lt;/sup> CFU/mL of Km A4 treatment group (&lt;i>p&lt;/i> &lt; 0.01). The results showed that Km A4 and Km A5 had good Caco-2 cell adhesion ability and modulated gut microbiota upon short-term administration in healthy mice.&lt;h4>Supplementary information&lt;/h4>The online version contains supplementary material available at 10.1007/s10068-023-01268-3.</pubmed_abstract><journal>Food science and biotechnology</journal><pubmed_title>Gut microbiota modulation via short-term administration of potential probiotic kefir yeast &lt;i>Kluyveromyces marxianus&lt;/i> A4 and A5 in BALB/c mice.</pubmed_title><pmcid>PMC9992467</pmcid><funding_grant_id>2021R1A2C2006817</funding_grant_id><pubmed_authors>Kim DH</pubmed_authors><pubmed_authors>Seo KH</pubmed_authors><pubmed_authors>Youn HY</pubmed_authors><pubmed_authors>Kim H</pubmed_authors><pubmed_authors>Kim HJ</pubmed_authors><pubmed_authors>Jang YS</pubmed_authors></additional><is_claimable>false</is_claimable><name>Gut microbiota modulation via short-term administration of potential probiotic kefir yeast &lt;i>Kluyveromyces marxianus&lt;/i> A4 and A5 in BALB/c mice.</name><description>Kefir yeast, &lt;i>Kluyveromyces marxianus&lt;/i>, has been evaluated for its potential probiotic properties-survivability, non-pathogenicity, and antioxidant and anti-microbial activities. However, host gut microbiota modulation of kefir yeasts remains unclear. Here, we compared kefir yeast strains &lt;i>K&lt;/i>. &lt;i>marxianus&lt;/i> A4 (Km A4) and &lt;i>K. marxianus&lt;/i> A5 (Km A5) with &lt;i>Saccharomyces boulardii&lt;/i> ATCC MYA-796 (Sb MYA-796) by investigating their adherence to colorectal adenocarcinoma (Caco-2) cells and gut microbiota modulation in BALB/c mice. The kefir yeast strains exhibited higher intestinal cell adhesion than Sb MYA-796 (&lt;i>p&lt;/i> &lt; 0.05). Bacteroidetes, Bacteroidales, and &lt;i>Bacteroides&lt;/i> were more abundant in the 1 × 10&lt;sup>8&lt;/sup> CFU/mL of Km A4 treatment group than in the control group (&lt;i>p&lt;/i> &lt; 0.05). Moreover, 1 × 10&lt;sup>8&lt;/sup> CFU/mL of Km A5 increased Corynebacteriales and &lt;i>Corynebacterium&lt;/i> compared to the 1 × 10&lt;sup>8&lt;/sup> CFU/mL of Km A4 treatment group (&lt;i>p&lt;/i> &lt; 0.01). The results showed that Km A4 and Km A5 had good Caco-2 cell adhesion ability and modulated gut microbiota upon short-term administration in healthy mice.&lt;h4>Supplementary information&lt;/h4>The online version contains supplementary material available at 10.1007/s10068-023-01268-3.</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Mar</publication><modification>2025-04-18T20:55:57.389Z</modification><creation>2025-04-07T08:59:25.363Z</creation></dates><accession>S-EPMC9992467</accession><cross_references><pubmed>36911334</pubmed><doi>10.1007/s10068-023-01268-3</doi></cross_references></HashMap>